Mateon Therapeutics Inc  

(Public, NASDAQ:MATN)   Watch this stock  
Find more results for NASDAQ:OXGN
0.704
+0.004 (0.54%)
Real-time:   3:13PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.67 - 0.73
52 week 0.67 - 0.73
Open 0.70
Vol / Avg. 71,840.00/927,444.00
Mkt cap 18.95M
P/E     -
Div/yield     -
EPS -0.54
Shares 26.54M
Beta 2.78
Inst. own 8%
Aug 2, 2016
Q2 2016 OXiGENE Inc Earnings Release (Estimated) Add to calendar
May 9, 2016
Q1 2016 OXiGENE Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -51.60% -47.18%
Return on average equity -56.07% -50.24%
Employees 13 -
CDP Score - -

Address

701 Gateway Blvd Ste 210
SOUTH SAN FRANCISCO, CA 94080-7041
United States - Map
+1-650-6357000 (Phone)
+1-650-6357001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Officers and directors

Frederick W. Driscoll Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
William D. Schwieterman M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Matthew M. Loar CPA Chief Financial Officer, Principal Accounting Officer
Age: 51
Bio & Compensation  - Reuters
David Chaplin Ph.D. Chief Scientific Officer, Director
Age: 59
Bio & Compensation  - Reuters
Simon C. Pedder Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
Gerald McMahon Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters